Health and Healthcare

AbbVie : ABBV

All AbbVie Articles

580 Articles

Chris Lange | Sep 26, 2018 at 8:50 AM EDT

Short Sellers Grow More Selective on Major Pharma Stocks

The September 14 short interest data have been compared with the previous figures, and short interest moves in these selected…

Chris Lange | Sep 19, 2018 at 1:50 PM EDT

Should AbbVie Be More Concerned About Its California Case for Humira?

AbbVie shares took a dip on Wednesday after it was announced that the pharma giant would be facing a lawsuit…

Chris Lange | Sep 13, 2018 at 9:55 AM EDT

Short Sellers Back Off Major Pharma Stocks

The August 31 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Aug 27, 2018 at 7:25 AM EDT

Short Sellers Can’t Make Up Their Minds on Major Pharma Stocks

The August 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical…

Jon C. Ogg | Aug 22, 2018 at 11:10 AM EDT

Why Big Pharma Stocks May Offer Big Upside and Dividends for the Second Half of 2018

Big Pharma is looking good for investors in the second half of 2018. That's the message from the research team…

Jon C. Ogg | Aug 15, 2018 at 11:50 AM EDT

Why Merrill Lynch Sees Health Care Sector Offering Solid Growth, and as Value and Defensive

The latest monthly Merrill Lynch RIC Report is quite favorable on the health care sector as an opportunity for investors.…

Chris Lange | Aug 10, 2018 at 9:50 AM EDT

Short Sellers Hike Bets in Major Pharma Stocks

The July 31 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Jul 27, 2018 at 11:20 AM EDT

Why AbbVie Earnings Were Not Enough for Investors

AbbVie released a better-than-expected quarterly report early on Friday, but shares retreated afterward.

Chris Lange | Jul 25, 2018 at 7:35 AM EDT

Major Pharma Stocks Scare Off Short Sellers

The July 13 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Jul 22, 2018 at 10:25 AM EDT

Amgen, Eli Lilly, Gilead and More Major Health Care Companies Reporting This Week

24/7 Wall St. has put together a preview of AbbVie, Eli Lilly, Gilead Sciences and some of the other, larger…

Lee Jackson | Jul 20, 2018 at 8:00 AM EDT

Top Analyst Bullish on Big Pharmaceutical Stocks Before Q2 Earnings

Four pharmaceutical industry leaders are poised to report second-quarter results next week, and one key analyst sees the relatively good…

Jon C. Ogg | Jul 12, 2018 at 9:05 AM EDT

Top Analyst Upgrades and Downgrades: AbbVie, Amazon, Anadarko, Broadcom, CA, Chipotle, ConocoPhillips, GE, Honeywell, J&J, 3M, NetApp, Netflix and More

The top analyst upgrades, downgrades and other research calls from Thursday include AbbVie, Amazon.com, Anadarko, Broadcom, Chipotle Mexican Grill, ConocoPhiilips,…

Chris Lange | Jul 12, 2018 at 8:50 AM EDT

Where Did Major Pharma Short Sellers Go?

The June 29 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Jul 11, 2018 at 10:15 AM EDT

AbbVie Slumps on Late-Stage Lymphoma Trial

AbbVie shares dipped on Wednesday after the company gave a less than impressive update from its late-stage lymphoma trial.

Chris Lange | Jul 7, 2018 at 8:15 AM EDT

Major Biopharma Catalysts on July’s FDA Calendar

Here 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates…

1 … 18 19 20 21 22 … 39

AbbVie : ABBV

All AbbVie Articles

Short Sellers Grow More Selective on Major Pharma Stocks

Should AbbVie Be More Concerned About Its California Case for Humira?

Short Sellers Back Off Major Pharma Stocks

Short Sellers Can’t Make Up Their Minds on Major Pharma Stocks

Why Big Pharma Stocks May Offer Big Upside and Dividends for the Second Half of 2018

Why Merrill Lynch Sees Health Care Sector Offering Solid Growth, and as Value and Defensive

Short Sellers Hike Bets in Major Pharma Stocks

Why AbbVie Earnings Were Not Enough for Investors

Major Pharma Stocks Scare Off Short Sellers

Amgen, Eli Lilly, Gilead and More Major Health Care Companies Reporting This Week

Top Analyst Bullish on Big Pharmaceutical Stocks Before Q2 Earnings

Top Analyst Upgrades and Downgrades: AbbVie, Amazon, Anadarko, Broadcom, CA, Chipotle, ConocoPhillips, GE, Honeywell, J&J, 3M, NetApp, Netflix and More

Where Did Major Pharma Short Sellers Go?

AbbVie Slumps on Late-Stage Lymphoma Trial

Major Biopharma Catalysts on July’s FDA Calendar

$10,000 Invested in XLK on New Year’s Eve Is Worth $13,434 Today

Is Ripple (XRP) Still A Good Crypto to Buy In 2026?

$10,000 Invested in XLK on New Year’s Eve Is Worth $13,434 Today

58% of Americans Think a 401(k) Balance Is Enough. 48% Have No Plan to Use It.

How a 73-Year-Old's First RMD Suddenly Pushed Her Effective Tax Rate to 40 Percent

$10,000 Invested in XLK on New Year’s Eve Is Worth $13,434 Today

Is Ripple (XRP) Still A Good Crypto to Buy In 2026?

AbbVie : ABBV

All AbbVie Articles

Short Sellers Grow More Selective on Major Pharma Stocks

Should AbbVie Be More Concerned About Its California Case for Humira?

Short Sellers Back Off Major Pharma Stocks

Short Sellers Can’t Make Up Their Minds on Major Pharma Stocks

Why Big Pharma Stocks May Offer Big Upside and Dividends for the Second Half of 2018

Why Merrill Lynch Sees Health Care Sector Offering Solid Growth, and as Value and Defensive

Short Sellers Hike Bets in Major Pharma Stocks

Why AbbVie Earnings Were Not Enough for Investors

Major Pharma Stocks Scare Off Short Sellers

Amgen, Eli Lilly, Gilead and More Major Health Care Companies Reporting This Week

Top Analyst Bullish on Big Pharmaceutical Stocks Before Q2 Earnings

Top Analyst Upgrades and Downgrades: AbbVie, Amazon, Anadarko, Broadcom, CA, Chipotle, ConocoPhillips, GE, Honeywell, J&J, 3M, NetApp, Netflix and More

Where Did Major Pharma Short Sellers Go?

AbbVie Slumps on Late-Stage Lymphoma Trial

Major Biopharma Catalysts on July’s FDA Calendar

$10,000 Invested in XLK on New Year’s Eve Is Worth $13,434 Today

Is Ripple (XRP) Still A Good Crypto to Buy In 2026?

$10,000 Invested in XLK on New Year’s Eve Is Worth $13,434 Today

Featured Reads

58% of Americans Think a 401(k) Balance Is Enough. 48% Have No Plan to Use It.

How a 73-Year-Old's First RMD Suddenly Pushed Her Effective Tax Rate to 40 Percent